Core Viewpoint - The announcement highlights the completion of the first subject enrollment in the Phase III clinical study of Annelazole Sodium Enteric-Coated Tablets for the treatment of gastroesophageal reflux disease (GERD), marking a significant milestone for the company and the industry [1] Group 1: Company Developments - The Phase III clinical study aims to comprehensively evaluate the efficacy and long-term safety of Annelazole Sodium Enteric-Coated Tablets for GERD, providing critical data support for regulatory approval of this indication [1] - Annelazole Sodium Enteric-Coated Tablets is the first and only PPI (Proton Pump Inhibitor) fully developed in China, representing a significant innovation in the domestic pharmaceutical market [1] Group 2: Industry Insights - According to ZhiShi Consulting data, the number of individuals suffering from GERD in China is approximately 38.3 million in 2024, with projections to increase to 42.4 million by 2032, indicating a growing market potential for GERD treatments [1]
四环医药：安奈拉唑钠用于反流性食管炎新适应症III期临床完成首例受试者入组